Abstract | Regulatory T cells (T REG ) are a subset of CD4 + T cells with a critical role in the prevention of autoimmunity. Whether defects in T REG contribute to the pathogenesis of rheumatoid arthritis (RA) is unclear. However, a variety of approved and experimental drugs for RA may work, in part, by promoting the function or increasing numbers of T REG . Furthermore, animal studies demonstrate that direct injection of T REG ameliorates a wide range of experimental models of inflammatory and autoimmune diseases. Thus, cell-based therapy with T REG has the potential to produce durable disease remission in patients with RA.
Background
The ultimate goal of therapy for patients with active rheuma toid arthritis (RA) and other autoimmune diseases is to restore normal immune function rather than to achieve broad immunosuppression. Evidence has accumu lated over the past decade that regulatory T cells (T REG ) could be an ideal target for therapies to induce durable remission of autoimmune and inflammatory disease (reviewed elsewhere 1 ). T REG are ideal for this purpose because they suppress inflammation in an antigen-specific manner. Furthermore, short-term therapy with T REG can lead to long-term inhibition of autoimmune disease in mouse models, and immunomodulatory agents can affect numbers and functioning of T REG in both mice and humans. Thus, approaches that bolster numbers or functioning of T REG could achieve selective and durable inhibition of pathologic inflammation without blocking protective immune responses against infection. In this Review, we discuss the use of small-molecule drugs, biological agents and direct T REG administration to increase numbers or promote the functions of T REG and to interrupt chronic inflammation in patients with RA ( Figure 1) .
T REG constitute 5-7% of CD4 + T cells in humans. 2, 3 These regulatory cells suppress immune responses through a variety of contact-dependent and contact-independent mechanisms.
4,5 Importantly, they have an inherently autoreactive T cell receptor (TCR) repertoire, and antigen recog nition through the TCR is required to suppress immune responses. 1, 6 The transcription factor forkhead box P3 (FOXP3) is critical for the genera tion and peripheral maintenance of T REG in both mice 7 and humans. 8 Mutations in FOXP3 or its regulatory regions cause an X-linked syndrome of immune dysregulation, polyendocrinopathy and enteropathy (IPEX) ch aracterized by massive polyclonal T cell activation and tissue in filtration. [8] [9] [10] [11] Immune ho meostasis in patients with IPEX can be successfully restored with hematopoietic stem cell transplantation following submyeloablative conditioning, since T REG exert a dominant regulatory effect that prevents systemic T cell activation and autoimmunity.
10,12-14 Moreover, other genetic loci that encode molecules involved in T REG function have been linked to auto immunity in genome-wide association studies. 15 Together, these observations have spurred further work on T REG in patients with common polygenic au toimmune diseases.
Three problems limit the use of FOXP3 expression alone to study T REG in humans. First, FOXP3 is expressed transiently in most activated human T cells, often without confer ring a regulatory phenotype. 16 high T cells are present in the synovial fluid of patients with RA and that their function is normal in vitro. 24, 26, 28, 29 However, these in vitro assays are not antigen-specific and the accumulation of polyclonal T REG in inflamed tissues might be a general phenomenon.
30,31 Thus, a critical question is whether numbers of antigen-specific T REG differ in healthy and affected individuals.
Two groups have reported that peripheral blood T REG isolated from patients with RA and from control individuals showed no difference in their ability to suppress effector T cell proliferation.
24,25 However, another group reported a striking defect in the capacity of T REG from patients with RA to suppress effector T cell proliferation. 32 These divergent results could reflect differences in the populations of patients, the methods used to purify T REG , or how the suppression assays were performed. Some evidence suggests that T REG from RA patients are defective in their ability to suppress the production of two principal proinflammatory cytokines-interferon (IFN)-γ and tumor necrosis factor (TNF)-by effector T cells. 25 This defect is associated with decreased surface expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4) on T REG and can be reversed by increasing CTLA-4 expression with phorbol ester treatment in vitro. 27 Importantly, effector T cells can become resistant to suppression by T REG in patients with autoimmune disease, and this observation can influence interpretation of the above results. 33 Overall, whether the reported defects in T REG function in patients with RA are the cause or result of chronic inflammation is not yet clear.
Effects of approved drugs on T REG
Although much still remains to be clarified about how T REG defects might contribute to the pathogenesis of RA, approaches that specifically boost T REG activity could be useful in the treatment of RA. High concentrations of TNF can block the immunosuppressive functions of T REG in vitro. 32 In this context, a notable observation is that treatment of RA patients with anti-TNF drugs bolsters T REG suppression of proinflammatory cytokine production. 25 For example, infliximab treatment restores the ability of T REG to suppress the production of IFN-γ and TNF by effector T cells, an effect that could be attribut able to either improved T REG function or increased sensitivity of effector T cells to such suppression. However, several additional findings suggest that TNF has direct effects on T REG that can be inhibited by infliximab. First, restoration of T REG function was accompanied by increased numbers of CD4 + CD25 high T cells in the blood of patients after anti-TNF treatment. Second, further work from the same group showed that these cells are induced T REG that express low levels of L-selectin (CD62L) and suppress effector cell cytokine production via transforming growth factor β and IL-10. 34 Finally, anti-TNF treatment decreased expression of TNF receptor 2 and GITR, and increased FOXP3 expression, within the CD4 + CD25
high population. Tocilizumab, an antibody that blocks the human IL-6 receptor, has shown efficacy in the treatment of RA [35] [36] [37] [38] and has been approved by European regulators for this indication. IL-6 is a proinflammatory cytokine produced by a variety of hematopoietic cells, including dendritic cells. IL-6 can block the immuno suppressive activity of T REG in mice. 39 By contrast, blockade of the IL-6 receptor with a monoclonal antibody in mice attenuates the severity of graft-versus-host disease and increases the absolute number of T REG in the spleens of treated mice through conversion of peripheral CD4 + T cells to T REG . 40 IL-6 prevents FOXP3 upregulation in human T cells in vitro. 41, 42 Thus, blockade of the IL-6 receptor may benefit patients with RA, at least in part, through augmenting the conversion of peripheral effector T cells to T REG , perhaps by preventing IL-6 from driving CD4 + cells toward a type 17 T-helper cell (T H 17) phenotype. 43 Importantly, IL-6 reportedly has no effect on the immunosuppressive capacity of T REG from the synovial fluid of patients with RA. 44 More work needs to be done, therefore, to elucidate the effects of IL-6 receptor blockade on the balance between T REG and T H 17 differentiation.
Another drug class that may affect T REG function in patients with RA includes the FDA-approved CD28 co-stimulation blocker, abatacept (a CTLA4-Ig fusion protein), and its higher-affinity derivative, belatacept. These drugs bind to the CD28 ligands CD80 and CD86 with a higher affinity than does the CD28 receptor, which prevents T-cell co-stimulation and interferes with T-cell-driven autoimmune processes. 45 Long-term belatacept treatment as part of an immunosuppressive regimen after kidney transplant had no effect on the percentage of circulat ing CD4 +
FOXP3
+ T cells but increased the percentage of FOXP3 + T cells in biopsy samples from kidneys undergoing acute rejection. 46 However, in mice, complete blockade of CD28 binding to CD80 and CD86 results in a precipitous loss of T REG . 47 These apparently contradictory results are probably related to the sub saturating doses of belatacept that were used in the human studies, 46 which resulted in selective loss of effector T cells and an increased proportion of T REG in inflamed tissue. 48, 49 Determining the optimal dose of CTLA4-Ig in patients with RA and other diseases will be critical if effector T cells are to be selectively inhibited while T REG function is preserved.
Rapamycin is an immunosuppressive small-molecule drug with a wide variety of effects on cells of both the innate and adaptive immune systems. 50 Importantly, rapamycin and other mTOR (mammalian target of rapamycin) inhibitors promote human T REG survival and differentiation and block effector T cell proliferation. 51, 52 Patients with RA who were treated with both the rapamycin derivative, everolimus, and methotrexate showed a greater response rate than patients treated with methotrexate alone. Thus, mTOR inhibition may ameliorate autoimmunity in part by promoting T REG function. However, to what extent the clinical efficacy of rapa mycin results from its effects on T REG is not known.
Experimental drugs that affect T REG
Toll-like receptors (TLRs) are expressed on cells of the immune system and respond to the presence of microbial products as well as to human self-molecules such as RNA and DNA. 53 T REG express multiple TLRs, and different TLR ligands regulate the immunosuppressive capacity of murine T REG in vitro and in vivo (reviewed elsewhere 54, 55 ). Mice deficient in TLR9 have elevated numbers of T REG in gut-associated lymphoid tissue, which highlights the importance of TLRs to T REG homeostasis. 56 Furthermore, synovial fluid from patients with RA contains TLR3 ligands, which promote inflammatory cytokine production in RA synovial fibroblasts. 57 In fact, hydroxychloroquine, a drug currently used to treat RA, may work in part by blocking TLR signaling.
58 IRS 954, an experimental antagonist of TLR7 and TLR9, reduces titers of antibodies to antinuclear antigens and decreases glomerulonephritis in lupus-prone (NZB × NZw F1) mice. 59 These results suggest that TLR antagonists could have therapeutic effects in patients with RA as a result of directly or indirectly boosting T REG function.
Trichostatin A is a small-molecule inhibitor of histone deacetlyases (HDACs) that increases numbers of T REG in normal mice by increasing thymic output of T REG .
60
A recent study demonstrated that the HDAC inhibitors MS-275 and vorinostat (suberoylanilide hydroxamic acid) induce FOXP3 expression and immunosuppressive capacity in human T cells activated in vitro.
61
Trichostatin A may work by increasing the acetylation and functioning of FOXP3, 60 or by preventing T REG from producing IL-17. 62 Thus, promotion of T REG differentiation might be a general result of HDAC inhibition, which suggests that HDAC inhibitors may, in future, have a role in therapy for autoimmune and inflam matory diseases. One HDAC inhibitor, vorinostat, has been approved by the FDA for the treatment of cuta neous T cell lymphoma, 63 and could be tested in patients with autoimmune disease.
IL-2 is a principal survival factor for T REG 64 and, in mice, its absence may contribute to defective T REG function in inflamed tissues. 31 Mice treated with a stabilized form of IL-2 demonstrate increased T REG proliferation and function.
31,65 IL-2, also known as aldesleukin, is currently used in cancer therapy, and some evidence suggests that it might also boost T REG numbers in humans. 66 Thus, administration of IL-2 could prove useful in the treatment of human autoimmune disease.
Cellular therapy moving to the clinic
First attempts to use cell-based approaches as therapy for inflammatory arthritis involved hematopoietic stem cell transplantation (HSCT) to treat active, destructive, refractory RA [67] [68] [69] and juvenile idiopathic arthritis. 70, 71 Although this treatment was curative for some patients, prolonged immunosuppression after HSCT was associated with a significant risk of infection, which limited the potential of this therapy. 72 However, data from these trials implicated T REG as a critical component of the regulatory state of the newly reconstituted immune system after transplant. In patients with juvenile idiopathic arthritis treated with HSCT, post-transplant reconstitution of CD4 + CD25 high T REG was more rapid than that of CD4 +
CD25
-cells. This preferential re covery of T REG could result from the relative resistance of T REG to apoptosis after genotoxic stress. 73 These results imply that other approaches to shifting the balance of the immune system away from inflammation and toward regulation, for example those that selectively bolster T REG numbers or function, could prove to be successful and less risky than HSCT.
One approach to boost numbers of T REG without myeloablative conditioning is to isolate T REG from patients, expand them in culture, and then re-infuse the cells. 74 Since T REG are only a small fraction of peripheral CD4 + T cells (5-7%), the most effective approach to T REG -based immunotherapy will require in vitro expansion of natural T REG under carefully controlled conditions to ensure the preservation of their regulatory capacity.
3,75
Ex vivo T REG expansion and re-infusion has successfully prevented or reversed a number of autoimmune diseases in mouse models, including models of inflam matory arthritis. [76] [77] [78] [79] [80] In the future, several new techniques may be incorporated into T REG -based immunotherapies to improve the efficacy and safety of this approach. For example, T REG may be targeted to inflamed tissues by transducing polyclonal T REG with antigen-specific T cell receptors, an approach previously used to modify effector T cells used in cancer immuno therapy. 81 Alternatively, antigen-specific T REG could be selected from a polyclonal population by stimulation with relevant peptides. 82 
Pitfalls of cellular therapy
Several pitfalls are possible in the treatment of patients with T REG . First, incomplete lineage commitment enables some human CD4 + FOXP3 + cells to express nuclear factor ROR-γt and to develop into IL-17-producing effector cells. 62, 83, 84 Moreover, recent data from mice suggest that some fully differentiated T REG may be unstable and able to trans-differentiate in vivo into effector memory T cells that produce pathogenic cytokines such as IFN-γ and IL-17. 95 Contamination of therapeutic T REG with these unstable T REG , or even with true autoreactive effector T cells, could lead to exacerbation rather than attenuation of the auto immune process. Second, T REG may be less effective in suppressing effector T cells in an autoimmune setting, and may even augment IL-17 production in vitro. 86, 87 Third, it is unclear whether a large polyclonal population of T REG would be able to interrupt an autoimmune process that targets antigens found in specific tissues. Fourth, polyclonal T REG therapy could result in generalized immuno suppression and increased susceptibility to infection. Finally, some patients with autoimmune disease may have poorly appreciated intrinsic defects in T REG function that cannot be overcome by infusion of large numbers of these defective cells. In spite of these potential concerns, however, clinical trials are underway to test the therapeutic potential of T REG in graft-versus-host disease.
91,92
Outlook Although existing drugs significantly reduce the morbidity and mortality associated with RA, these therapies are not curative. Several drugs that affect T REG numbers or function have shown efficacy in the treatment of RA. These results imply that direct administration of T REG could be an ideal therapy to induce durable remission of RA, as these cells persist in vivo and act in an antigen-specific manner. Thus, approaches that bolster T REG numbers and functions could be a fruitful means of selectively and durably inhibit ing pathologic inflammation without blocking pr otective immune responses against infection.
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